Nivolumab for the Treatment of Patients with Metastatic Non‐Clear Cell Renal Cell Carcinoma (nccRCC): A Single‐Institutional Experience and Literature Meta‐Analysis

INTRODUCTION: Nivolumab alone and in combination with ipilimumab is approved for the treatment of patients with metastatic renal cell carcinoma (RCC) who received prior vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR‐TKI) and those who are treatment naive, respectively....

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Chahoud, Jad, Msaouel, Pavlos, Campbell, Matthew T., Bathala, Tharakeswara, Xiao, Lianchun, Gao, Jianjun, Zurita, Amado J., Shah, Amishi Yogesh, Jonasch, Eric, Sharma, Padmanee, Tannir, Nizar M.
Format: Artigo
Langue:Inglês
Publié: John Wiley & Sons, Inc. 2019
Sujets:
Genitourinary Cancer
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066696/
https://ncbi.nlm.nih.gov/pubmed/32162795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0372
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires